Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 3Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Digoxin × Clear all
NCT04141995 2025-08-07

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

University of Nebraska

Phase 2 Terminated
11 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00281021 2018-03-29

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

University of Louisville

Phase 2 Terminated
26 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01887288 2018-02-22

Capecitabine With Digoxin for Metastatic Breast Cancer

Western Regional Medical Center

Phase 2 Terminated
16 enrolled 1 chart
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡